A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Required: PD-L1 (CD274) tumour proportion score (TPS) ≥ 1% (TPS ≥ 1%)

Programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥ 1% (per local report) [Sub Study 2]

Excluded: EGFR mutation

Participants with epidermal growth factor receptor mutations ... for which targeted therapy is approved in the first line per local standard of care [excluded].

Excluded: ALK fusion

Participants with ... anaplastic lymphoma receptor fusions ... for which targeted therapy is approved in the first line per local standard of care [excluded].

Cannot have received: systemic therapy

Prior systemic therapy received for advanced or mNSCLC [Sub Study 2]

Cannot have received: anti-TIGIT therapy

Prior exposure to an anti-T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif domains (TIGIT) therapy or immune-oncology agent such as anti-programmed cell death protein 1 (PD-1), anti-PD-L1, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), or any other anti-cancer therapy targeting immune-regulatory receptors or mechanisms [Sub Study 2]

Cannot have received: anti-PD-1 therapy

Prior exposure to ... anti-programmed cell death protein 1 (PD-1) ... [Sub Study 2]

Cannot have received: anti-PD-L1 therapy

Prior exposure to ... anti-PD-L1 ... [Sub Study 2]

Cannot have received: anti-CTLA-4 therapy

Prior exposure to ... anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) ... [Sub Study 2]

Cannot have received: anti-VEGF therapy

Prior exposure to anti-vascular endothelial growth factor (VEGF) therapy [Sub Study 2]

Cannot have received: platinum-based chemotherapy (cisplatin, carboplatin)

Exception: medical contraindication to protocol-specified platinum doublet regimens or ramucirumab

Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab [Sub Study 2]

Cannot have received: antibody-drug conjugate (ramucirumab)

Exception: medical contraindication

Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab [Sub Study 2]